A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
← catalyst calendarNCT07723833 · readout in 90 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
152estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-27 | actual | When the study began enrolling |
| Primary completion | 2026-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Elecoglipron Reference Formulation Dose A
- Drug: Elecoglipron Test formulation 1 Dose A
- Drug: Elecoglipron Reference Formulation Dose B
- Drug: Elecoglipron Test formulation 1 Dose B
- Drug: Elecoglipron Test formulation 2 Dose A
- Drug: Elecoglipron Test formulation 2 Dose B
Primary outcomes
what the primary-completion date above is the date OFMaximum observed drug concentration (Cmax)
measured At pre-defined intervals from Day 1 to Day 15
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
measured At pre-defined intervals from Day 1 to Day 15
Area under concentration-time curve from time 0 to infinity (AUCinf)
measured At pre-defined intervals from Day 1 to Day 15
Time to reach maximum observed concentration (tmax)
measured At pre-defined intervals from Day 1 to Day 15
Terminal elimination rate constant (λz)
measured At pre-defined intervals from Day 1 to Day 15
Terminal elimination half-life (t1/2λz)
measured At pre-defined intervals from Day 1 to Day 15
Apparent total body clearance (CL/F)
measured At pre-defined intervals from Day 1 to Day 15
Apparent volume of distribution based on the terminal phase (Vz/F)
measured At pre-defined intervals from Day 1 to Day 15
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf)
measured At pre-defined intervals from Day 1 to Day 15
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast)
measured At pre-defined intervals from Day 1 to Day 15
Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax)
measured At pre-defined intervals from Day 1 to Day 15
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed